Last reviewed · How we verify
Salicylic Acid (6%)
Salicylic acid works as a keratolytic agent that softens and dissolves the outer layer of skin, promoting exfoliation and removal of dead skin cells.
Salicylic acid works as a keratolytic agent that softens and dissolves the outer layer of skin, promoting exfoliation and removal of dead skin cells. Used for Acne vulgaris, Psoriasis, Warts.
At a glance
| Generic name | Salicylic Acid (6%) |
|---|---|
| Sponsor | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
| Drug class | Keratolytic agent |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Salicylic acid is a beta hydroxy acid (BHA) that penetrates the skin and breaks down the bonds between corneocytes in the stratum corneum, facilitating desquamation. It also has mild anti-inflammatory and antimicrobial properties. At 6% concentration, it is commonly used for topical treatment of hyperkeratotic skin conditions.
Approved indications
- Acne vulgaris
- Psoriasis
- Warts
- Calluses and corns
- Seborrheic keratosis
Common side effects
- Skin irritation
- Erythema
- Dryness
- Peeling
- Burning sensation
Key clinical trials
- Performance of Reinforced 3D-Printed Versus Direct Bulk-Filled Resin Composites for Restoring Extensive Class II Cavities in Vital Molars (NA)
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (PHASE2, PHASE3)
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (PHASE3)
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (PHASE3)
- Combination Therapy for Warts: Candida Antigen vs. Topical Keratolytic (PHASE2)
- Autonomic Control of the Circulation and VDR (EARLY_PHASE1)
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer (PHASE3)
- Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: